EyePoint Valuation Multiples

EyePoint Overview

About EyePoint

EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Founded

2008

HQ

Employees

165

Website

eyepoint.bio

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $24M

EBITDA: ($263M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

EyePoint Financials

EyePoint reported last 12-month revenue of $24M and negative EBITDA of ($263M).

In the same LTM period, EyePoint generated $22M in gross profit, ($263M) in EBITDA losses, and had net loss of ($244M).

EyePoint P&L

In the most recent fiscal year, EyePoint reported revenue of $31M and EBITDA of ($229M).

EyePoint expects next 12-month revenue of XXX and NTM EBITDA of XXX

EyePoint Stock Performance

EyePoint has current market cap of $1B, and enterprise value of $1B.

EyePoint's stock price is $18.01.

EyePoint Valuation Multiples

EyePoint trades at 54.3x EV/Revenue multiple, and (5.0x) EV/EBITDA.

EyePoint Financial Valuation Multiples

As of March 29, 2026, EyePoint has market cap of $1B and EV of $1B.

Equity research analysts estimate EyePoint's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

EyePoint has a P/E ratio of (6.1x).

EyePoint Margins & Growth Rates

EyePoint's revenue in the last 12 month declined by (45%).

EyePoint's revenue per employee in the last FY averaged $0.1M.

EyePoint's rule of 40 is (1136%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

EyePoint's rule of X is (1203%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

EyePoint Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

EyePoint M&A Activity

EyePoint acquired XXX companies to date.

Last acquisition by EyePoint was on XXXXXXXX, XXXXX. EyePoint acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

EyePoint Investment Activity

EyePoint invested in XXX companies to date.

EyePoint made its latest investment on XXXXXXXX, XXXXX. EyePoint invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).